Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
27 sept. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 sept. 2022 17h36 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
25 août 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
17 août 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
08 août 2022 16h03 HE
|
Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...
Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®
15 juin 2022 07h55 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Launch of New Therapies Amplifies Competition in the Dry Eye Disease Pipeline Landscape, Pronounces DelveInsight
07 juil. 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, July 07, 2021 (GLOBE NEWSWIRE) -- Launch of New Therapies Amplifies Competition in the Dry Eye Disease Pipeline Landscape, Pronounces DelveInsight The Dry Eye disease pipeline...
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops
17 mai 2021 09h00 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., May 17, 2021 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of...
Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02
06 mai 2021 10h00 HE
|
AGC Biologics
Seattle, May 06, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to...
Utah Doctors Announce a Successful New Option for Treating Dry Eye Disease
06 mai 2014 09h01 HE
|
The Eye Institute of Utah
SALT LAKE CITY, UT--(Marketwired - May 6, 2014) - Doctors and staff at The Eye Institute of Utah (EIU) are pleased to announce that numerous patients suffering from dry eye disease are finding...